Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH1 Gene Mutation”

74 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 74 results

Large-scale testing (Phase 3)Active Not RecruitingNCT06780930
What this trial is testing

Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

Who this might be right for
Residual or Recurrent Grade 2 IDH Mutant Glioma
Servier 57
Testing effectiveness (Phase 2)Looking for participantsNCT07507760
What this trial is testing

Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients

Who this might be right for
Acute Myeloid Leukemia With Gene Mutations
PETHEMA Foundation 50
Early research (Phase 1)Looking for participantsNCT06543381
What this trial is testing

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

Who this might be right for
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center 15
Early research (Phase 1)Ended earlyNCT05814536
What this trial is testing

IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor

Who this might be right for
Cholangiocarcinoma With IDH1 MutationSolid Tumors With IDH1 Mutation
AnHeart Therapeutics Inc. 9
Early research (Phase 1)Study completedNCT02481154
What this trial is testing

Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation

Who this might be right for
Glioma
Institut de Recherches Internationales Servier 95
Early research (Phase 1)Study completedNCT03564821
What this trial is testing

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Who this might be right for
IDH1 Mutation Myeloid Neoplasms
Massachusetts General Hospital 18
Not applicableStudy completedNCT06181734
What this trial is testing

Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC

Who this might be right for
Acute Myeloid Leukemia (AML)
iOMEDICO AG 8
Large-scale testing (Phase 3)Looking for participantsNCT06465953
What this trial is testing

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

Who this might be right for
Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)Myelodysplastic Syndromes (MDS)
Institut de Recherches Internationales Servier 48
Large-scale testing (Phase 3)Active Not RecruitingNCT05987358
What this trial is testing

A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.

Who this might be right for
Biliary Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 165
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07664839
What this trial is testing

Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

Who this might be right for
Acute Myeloid LeukemiaNPM1 MutationIDH1 Mutation+1 more
Shen yang 148
Early research (Phase 1)Looking for participantsNCT06291987
What this trial is testing

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

Who this might be right for
Myeloproliferative Neoplasms
University of Chicago 18
Early research (Phase 1)WithdrawnNCT04955938
What this trial is testing

Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

Who this might be right for
IDH MutationIDH1 MutationIDH2 Gene Mutation+2 more
University of Chicago
Testing effectiveness (Phase 2)Looking for participantsNCT06707493
What this trial is testing

Ivosidenib as Post-HSCT Maintenance for AML

Who this might be right for
IDH1 MutationAcute Myeloid Leukemia (AML)Hematopoietic Stem Cell Transplant (HSCT)
Massachusetts General Hospital 75
Not applicableUnknownNCT03204838
What this trial is testing

IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients

Who this might be right for
Acute Myeloid Leukemia (AML)
Hospital General de Mexico 100
Not applicableUnknownNCT02333513
What this trial is testing

Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Who this might be right for
Recurrent High-grade Glioma
Hebei Yanda Hospital 100
Large-scale testing (Phase 3)Looking for participantsNCT06127407
What this trial is testing

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Who this might be right for
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC 136
Testing effectiveness (Phase 2)Active Not RecruitingNCT06478212
What this trial is testing

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

Who this might be right for
IDH1-mutant GliomaIDH2-mutant Glioma
Institut de Recherches Internationales Servier 51
Not applicableLooking for participantsNCT07315542
What this trial is testing

Diagnostic and Therapeutic Targets in Cartilaginous Tumours

Who this might be right for
ChondrosarcomasCartilage Tumours
St. Anne's University Hospital Brno, Czech Republic 300
Testing effectiveness (Phase 2)Looking for participantsNCT05588141
What this trial is testing

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Who this might be right for
Brain TumorCancer
National Cancer Institute (NCI) 96
Testing effectiveness (Phase 2)UnknownNCT03666559
What this trial is testing

Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation

Who this might be right for
Recurrent IDH1/2 Mutated Glioma
Assistance Publique - Hôpitaux de Paris 8
Next Page